| SEC Form 4 |  |
|------------|--|
|------------|--|

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

|  | Washington, D.C. 2   | :0549  |                                |  | C  | MB APPRO  | VAL   |
|--|--|--|--------------------------------|--|--|---|---|
| Section 16. Form 4 or Form 5 ´<br>obligations may continue. See<br>Instruction 1(b). Filed pursuant to S   | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP<br>Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934<br>or Section 30(h) of the Investment Company Act of 1940 |  |                                |  | Estima   | lumber:<br>ted average burder<br>per response:  | 3235-0287<br>n<br>0.5                               |
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.   |  |  |                                |  |  |   |   |
|  | ame <b>and</b> Ticker or Trading<br>t <u>Sciences Ltd.</u> [ R   |  |                                | (Check all appl                            | icable)  | Person(s) to Iss  |   |
|  |  |  |                                | Direct                                     |  | 10% Ov<br>Other (s  |   |
| (Last) (Pilst) (Midule) 09/10/2024   | Earliest Transaction (Mont<br>24   | h/Day/Year)  |                                | below                                      | r (give title<br>)   | below)  | specity   |
| C/O ROIVANT SCIENCES LTD.  |  |  |                                |  |  |   |   |
| 7TH FLOOR, 50 BROADWAY 4. If Amendm  | dment, Date of Original Fil  | ed (Month/Day/   | /Year)                         | 6. Individual or Line)                     | Joint/Group  | Filing (Check Ap  | plicable  |
| (Street)<br>LONDON X0 SW1H 0DB   |  |  |                                |  | filed by More  | Reporting Person<br>than One Repor  |   |
| (City) (State) (Zip)   |  |  |                                |  |  |   |   |
| Table I - Non-Derivative Secur   | urities Acquired, D  | isposed of,  | or Benefic                     | cially Owned                               | d  |   |   |
| Date Exec<br>(Month/Day/Year) if an  | saction 2A. Deemed 3. 4. Securities Acquire Execution Date, Transaction Disposed Of (D) (  |  |                                | and Securities<br>Benefic<br>Owned         | Beneficially (D)<br>Owned Following (I)  |   | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |
|  | Code V   | Amount   | (A) or<br>(D) Pr               | rice Reporte<br>Transac<br>(Instr. 3       | tion(s)  | 1   | (Instr. 4)  |
| Common Shares 09/10/2024   | А  | 16,406(1)  | D <b>A</b>                     | \$0 <sup>(1)</sup> 99                      | 9,040  | D   |   |
| Table II - Derivative Securit<br>(e.g. puts. calls w   | ities Acquired, Dis<br>warrants, options   | •  |                                |  |  |   |   |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)     2.     3. Transaction<br>Date<br>(Month/Day/Year)     3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year)     4.     5.       1. Title of<br>Derivative<br>Security     3. Transaction<br>(Month/Day/Year)     3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year)     4.     5.       1. Transaction<br>Derivative<br>Security     3. Transaction<br>(Month/Day/Year)     3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year)     4.     5. | 5. Number 6. Date Exer<br>of Expiration D  | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) 7. Title and Ar<br>of Securities<br>Underlying<br>Derivative Sec<br>(Instr. 3 and 4 |                                | ount 8. Price of<br>Derivative<br>Security | 9. Number<br>derivative<br>Securities<br>Beneficiall<br>Owned<br>Following<br>Reported<br>Transactio<br>(Instr. 4) | tive Ownership<br>ties Form:<br>cially Direct (D)<br>d or Indirect<br>ring (I) (Instr. 4<br>action(s) | Beneficial<br>Ownership<br>t (Instr. 4)             |
| Code V (A  | (A) (D) Date<br>Exercisable  | Expiration<br>Date T   | Amo<br>or<br>Num<br>of<br>Shar | ıber                                       |  |   |   |
|  |  |  |                                |  |  |   |   |
| Stock<br>Option<br>(Right to<br>Buy) \$12.19 09/10/2024 A 27   | 27,894 (2)   |  | Shares 27,8                    | 894 \$0                                    | 27,894   | D   |   |

Compensation Policy The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the company source service through such date.

2. Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equit Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date.

| By: /s/ Jo Chen, as Attorn | <u>ney-in-</u> 00/12/2024 |
|----------------------------|---------------------------|
| Fact for Ilan Oren         | 09/12/2024                |

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.